Clinical trial
A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT04880876 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Lead sponsor
- AbbVie
- Phase
- Phase 3
- Overall status
- Enrolling by invitation
- Start date
- August 13, 2021
- Completion date
- December 31, 2032
- Enrollment
- 124 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.